Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) has the potential in the type 1 diabetes mellitus research that is a potent inhibitor of 12/15-Lipoxygenases (LO) [1].

High glucose or 12(S)-HETE significantly enhanced transendothelial dextran transport, which was further amplified when combined. The introduction of the 12/15-LO inhibitor, CDC, resulted in a partial reduction of dextran transport [1].

Elevated glucose and 12(S)-hydroxyeicosatetraenoic acid (HETE) levels can modify phosphorylation levels of vascular endothelial (VE)-cadherin and β‐catenin without affecting their total protein expression. Conversely, the 12/15-LO inhibitor, Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC), counteracts the impact of high glucose on protein phosphorylation, thereby preserving the integrity of the endothelial cell barrier. These findings were substantiated by a mouse diabetes mellitus model [1].